Palm Springs, CANCT07344558Now EnrollingIRB Ready

Idiopathic Pulmonary Fibrosis (IPF) Clinical Trial in Palm Springs, CA

Access cutting-edge idiopathic pulmonary fibrosis (ipf) treatment through this clinical trial at a research site in Palm Springs. Study-provided care at no cost to qualified participants.

Sponsored by Mannkind Corporation

Quick Self-Assessment

See if you qualify for this Palm Springs location

Preparing your pre-screening questions…

Expert Care in Palm Springs

Access idiopathic pulmonary fibrosis (ipf) specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related idiopathic pulmonary fibrosis (ipf) treatment provided free

Apply for This Palm Springs Location

Check if you qualify for this idiopathic pulmonary fibrosis (ipf) clinical trial in Palm Springs, CA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Palm Springs

    Convenient for CA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Palm Springs site if eligible
  4. 4Begin participation

About This Idiopathic Pulmonary Fibrosis (IPF) Study in Palm Springs

MKC-NI-002 is a Phase 1b, randomized, double-blind, placebo-controlled study of nintedanib inhalation powder (MNKD-201) in patients with Idiopathic Pulmonary Fibrosis (IPF). The trial consists of Multiple Ascending Doses (MAD) with the primary objective to evaluate safety, tolerability and pharmacokinetics (PK) of MNKD-201 compared to placebo in patients with IPF.

Sponsor: Mannkind Corporation

Who Can Participate

Inclusion Criteria

Is ≥40 to ≤85 years of age at the time of signing the informed consent form.
Diagnosis of IPF
Either treatment-naive or is currently on background pirfenidone or nerandomilast on a stable dose for at least 3 months prior to Screening.
Has FVC \>45% of predicted of normal, as determined by the central spirometry reader, during Screening.
DLCO corrected for hemoglobin \[Visit 1\] ≥40% of predicted of normal, within 12 months of Screening. If no historical DLCO is available prior to Screening, this is to be done during Screening and read locally.
Has a body weight \>40 kg (\>88 lbs.) at Screening.
For female participants of childbearing potential, agreement to use acceptable birth control
For male participants who can father a child and are having intercourse with females of childbearing potential, agreement to use a protocol-recommended method of contraception
Is capable of performing spirometry, as required by the study procedures and ATS guidelines.
CT chest within 2 years of Screening, consistent with an IPF diagnosis, per investigator assessment.

Exclusion Criteria

Known explanation for interstitial lung disease, including but not limited to radiation, sarcoidosis, hypersensitivity pneumonitis, and bronchiolitis obliterans organizing pneumonia.
Diagnosis of any connective tissue disease, including but not limited to scleroderma/systemic sclerosis, polymyositis/dermatomyositis, systemic lupus erythematosus, and rheumatoid arthritis, regardless of whether or not it is presumed to be related to their pulmonary fibrosis diagnosis.
Major extrapulmonary physiological restriction (e.g., chest wall abnormality, large pleural effusion), as determined by the investigator.
Significant Cardiovascular diseases
Recent systemic infection within 4 weeks before the Screening visit or symptomatic viral or bacterial infection at time of Screening.
Prior hospitalization for confirmed coronavirus disease 2019 (COVID-19), acute exacerbation of IPF or any lower respiratory tract infection within 3 months of Screening.
Has a history of asthma, with the exception of resolved childhood asthma.
Has known obstructive lung disease
Alanine aminotransferase (ALT), aspartate aminotransferase (AST), or total bilirubin \>1.5 times the upper limit of normal (ULN) during Screening.
Advanced liver and kidney function.
Current or recent (within 30 days of Screening) use of nintedanib.
Use of prednisone \>10 mg/day within 1 month prior to Screening, or other significant immunosuppression
Active lung cancer (primary or metastatic) or any cancer requiring chemotherapy or radiation therapy within 3 years, except appropriately treated non-melanoma skin cancer, localized non-malignant prostate cancer, or in situ carcinoma of uterine cervix.
Has participated in another clinical study of a new chemical entity, new device, or a prescription medicine within the 1 month before Screening
Current alcohol, medication, or illicit drug abuse
Has lost more than 400 mL blood, e.g., as a blood donor, or donor of blood products, during the 3 months prior to Screening.
Has received a live vaccine within the 3 months prior to the first dose of study drug.
Smokes (any substance including electronic cigarettes and marijuana) within 3 months prior to Screening or is an ex-cigarette smoker who gave up \<1 year ago.
Has oxygen requirement of \> 6 liters/min at rest.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Palm Springs?

Yes, this clinical trial (NCT07344558) has an active research site in Palm Springs, CA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Idiopathic Pulmonary Fibrosis (IPF) Treatment Options in Palm Springs, CA

If you're searching for idiopathic pulmonary fibrosis (ipf) treatment options in Palm Springs, CA, this clinical trial (NCT07344558) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Palm Springs research site is actively enrolling participants for this clinical trial. You'll receive care from experienced idiopathic pulmonary fibrosis (ipf) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all idiopathic pulmonary fibrosis (ipf) clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Fibrosis Trials in Palm Springs, CA

See all pulmonary fibrosis clinical trials recruiting in Palm Springs — not just this study.

Browse Pulmonary Fibrosis Trials in Palm Springs →

Browse More Trials by Condition

Pulmonary Fibrosis TrialsInterstitial Cystitis TrialsFibromyalgia TrialsInterstitial Lung Disease TrialsAll Conditions →

Ready to Join in Palm Springs?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Palm Springs, CA